Mitochondrial Peptides Show Promise as Novel Antidiabetic Therapies

Type 2 Diabetes (T2D) is a global health crisis characterized by insulin resistance and impaired insulin secretion, affecting millions worldwide. Current treatments often have limitations, driving the search for novel therapeutic targets. Mitochondrial-derived peptides (MDPs), such as MOTS-c and Humanin, are emerging as crucial regulators of metabolism and cellular health. This study addresses the specific antidiabetic functions and underlying mechanisms of these peptides, a knowledge gap critical for developing new T2D interventions.

Treatment with MOTS-c significantly enhanced glucose uptake in L6 myotubes by 35% compared to untreated controls, indicating improved insulin sensitivity. Humanin demonstrated a 28% reduction in hepatic glucose production in HepG2 cells, suggesting a direct impact on liver glucose metabolism. In DIO mice, MOTS-c administration led to a remarkable 2.5-fold increase in the insulin sensitivity index and a 40% reduction in fasting blood glucose levels compared to the vehicle group. Humanin treated mice exhibited a 32% decrease in HbA1c levels and showed p<0.001 improvement in glucose tolerance tests. Both peptides also significantly reduced systemic inflammatory markers like IL-6 by p<0.05. The most significant finding was that MOTS-c treatment restored mitochondrial respiratory capacity by an average of 60% in pancreatic beta cells, preventing apoptosis and improving insulin secretion by 45% in diabetic mice, directly addressing the root cause of T2D.